search results for 

Research and development

Our R & D activities will continue to play a key role in securing the Group’s long-term growth through innovations and new therapies.

We plan to increase the Group’s R & D spending in 2014. About 4% to 5% of our product sales will be reinvested in research and development.

Market-oriented research and development with strict time-to-market management processes is crucial for the success of new products. We continually review our R & D results using clearly defined milestones. Innovative ideas, product development, and therapies with a high level of quality will continue to be the basis for future market-leading positions. Given the continued cost-containment efforts in the health care sector, cost efficiency combined with a strong quality focus is acquiring ever-greater importance in product development, and in the improvement of treatment concepts.

In 2013, Fresenius Medical Care has reorganized its R & D department. In three steps, we plan to build up a global R & D function that can efficiently develop outstanding products.

  • Global portfolio management
    The new organization will allow us to concentrate our development pipeline more on growth areas and growing markets.
  • Global product platforms
    We want to unify the basic functions of our therapy systems internationally through the global management of product development and the creation of a modular system. We want to shorten development times, use economies of scale in purchasing, and increasingly focus development resources on innovation and new technology.
  • Global project management and global development processes
    The introduction of global project management standards, structures, and development processes will allow us to further increase the efficiency of our project management.

Another focus of our development work is infusion and nutrition therapies and the development of generic IV drugs at Fresenius Kabi. In particular, we are concentrating on being in a position to offer the corresponding generic drug formulation promptly upon the expiration of patents for originator drugs. We are also working to expand our portfolio to include additional ready-to-use IV drugs.

We want our medical devices to make a contribution to the safe and effective application of infusion solutions and clinical nutrition. That is why we will continue to develop new products and improve on existing ones in this segment. In transfusion technology, we are focusing our development work on devices and disposables that enable the safe, user-friendly, and efficient production of blood products and the treatment of specific diseases, in particular autoimmune diseases.

Back to: